Cargando…
Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057902/ https://www.ncbi.nlm.nih.gov/pubmed/36984543 http://dx.doi.org/10.3390/medicina59030541 |
_version_ | 1785016483116482560 |
---|---|
author | Tanaka, Tomohiro Okamoto, Masaki Matsuo, Norikazu Naitou-Nishida, Yoshiko Nouno, Takashi Kojima, Takashi Nishii, Yuuya Uchiyashiki, Yoshihiro Takeoka, Hiroaki Nagasaki, Yoji |
author_facet | Tanaka, Tomohiro Okamoto, Masaki Matsuo, Norikazu Naitou-Nishida, Yoshiko Nouno, Takashi Kojima, Takashi Nishii, Yuuya Uchiyashiki, Yoshihiro Takeoka, Hiroaki Nagasaki, Yoji |
author_sort | Tanaka, Tomohiro |
collection | PubMed |
description | The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of HCQ therapy in patients treated in our hospital, and discuss the advantages and disadvantages of HCQ therapy for patients with COVID-19. A representative case was a 66-year-old woman who had become infected with severe acute respiratory syndrome coronavirus 2 and was diagnosed as having COVID-19 pneumonia via polymerase chain reaction. She was refractory to treatment with levofloxacin, lopinavir, and ritonavir, while her condition improved after beginning HCQ therapy without severe side effects. We show the tolerability of HCQ therapy for 27 patients treated in our hospital. In total, 21 adverse events occurred in 20 (74%) patients, namely, diarrhea in 11 (41%) patients, and elevated levels of both aspartate aminotransferase and alanine transaminase in 10 (37%) patients. All seven grade ≥ 4 adverse events were associated with the deterioration in COVID-19 status. No patients discontinued HCQ treatment because of HCQ-related adverse events. Two patients (7%) died of COVID-19 pneumonia. In conclusion, HCQ therapy that had been performed for COVID-19 was well-tolerated in our case series. |
format | Online Article Text |
id | pubmed-10057902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100579022023-03-30 Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Tanaka, Tomohiro Okamoto, Masaki Matsuo, Norikazu Naitou-Nishida, Yoshiko Nouno, Takashi Kojima, Takashi Nishii, Yuuya Uchiyashiki, Yoshihiro Takeoka, Hiroaki Nagasaki, Yoji Medicina (Kaunas) Case Report The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of HCQ therapy in patients treated in our hospital, and discuss the advantages and disadvantages of HCQ therapy for patients with COVID-19. A representative case was a 66-year-old woman who had become infected with severe acute respiratory syndrome coronavirus 2 and was diagnosed as having COVID-19 pneumonia via polymerase chain reaction. She was refractory to treatment with levofloxacin, lopinavir, and ritonavir, while her condition improved after beginning HCQ therapy without severe side effects. We show the tolerability of HCQ therapy for 27 patients treated in our hospital. In total, 21 adverse events occurred in 20 (74%) patients, namely, diarrhea in 11 (41%) patients, and elevated levels of both aspartate aminotransferase and alanine transaminase in 10 (37%) patients. All seven grade ≥ 4 adverse events were associated with the deterioration in COVID-19 status. No patients discontinued HCQ treatment because of HCQ-related adverse events. Two patients (7%) died of COVID-19 pneumonia. In conclusion, HCQ therapy that had been performed for COVID-19 was well-tolerated in our case series. MDPI 2023-03-10 /pmc/articles/PMC10057902/ /pubmed/36984543 http://dx.doi.org/10.3390/medicina59030541 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Tanaka, Tomohiro Okamoto, Masaki Matsuo, Norikazu Naitou-Nishida, Yoshiko Nouno, Takashi Kojima, Takashi Nishii, Yuuya Uchiyashiki, Yoshihiro Takeoka, Hiroaki Nagasaki, Yoji Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title | Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title_full | Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title_fullStr | Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title_full_unstemmed | Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title_short | Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine |
title_sort | case series of patients with coronavirus disease 2019 pneumonia treated with hydroxychloroquine |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057902/ https://www.ncbi.nlm.nih.gov/pubmed/36984543 http://dx.doi.org/10.3390/medicina59030541 |
work_keys_str_mv | AT tanakatomohiro caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT okamotomasaki caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT matsuonorikazu caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT naitounishidayoshiko caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT nounotakashi caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT kojimatakashi caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT nishiiyuuya caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT uchiyashikiyoshihiro caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT takeokahiroaki caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine AT nagasakiyoji caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine |